Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8787560 | Journal of Thoracic Oncology | 2018 | 11 Pages |
Abstract
We showed the resistance mechanism to EGFR-TKI focusing on first- and second-line osimertinib using ENU mutagenesis screening. Additional T854A and L792H on C797S/activating-mutation were found as afatinib resistance and not as gefitinib resistance. Thus, compared to afatinib, the first-generation EGFR-TKI might be preferable as second-line treatment to C797S/activating-mutation emerging after first-line osimertinib treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Ken MD, PhD, Naohiko MD, PhD, Makoto MD, PhD, Naoya PhD, Ryohei PhD,